A Study of the Safety, Tolerability, and Pharmacokinetics of NYR-BI03 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 19, 2025

Primary Completion Date

July 24, 2025

Study Completion Date

July 25, 2025

Conditions

Healthy

Interventions

DRUG

NYR-BI03

Participants receive NYR-BI03 nanosuspension formulated for continuous intravenous infusion to be given over 3 hours or 6 hours.

DRUG

Matching placebo (all cohorts)

Administered as a continuous intravenous infusion over 3 hours or 6 hours

Trial Locations (1)

Scientia Clinical Research Ltd, Randwick

All Listed Sponsors

lead

Nyrada Pty Ltd

INDUSTRY

NCT06894862 - A Study of the Safety, Tolerability, and Pharmacokinetics of NYR-BI03 in Healthy Participants | Biotech Hunter | Biotech Hunter